Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence Cathrin Rohleder, Juliane K. Müller, Bettina Lange and F. M. Leweke Frontiers in Pharmacology, 2016, Volume 7, Article 422. doi: 10.3389/fphar.2016.00422 There is urgent need for the development of mechanistically different and less side-effect prone antipsychotic compounds. The endocannabinoid system has been suggested to represent a potential new target in this indication. While the chronic use of cannabis itself has been considered a risk factor contributing to the development of schizophrenia, triggered by the phytocannabinoid delta-9-tetra-hydro-cannabinol (19-THC), cannabidiol, the second most important phytocannabinoid, appears to have no psychotomimetic potential. [...]
Lire la suiteTherapeutic Potential of Cannabinoids in Psychosis. Leweke F.M., Mueller J.K., Lange B., Rohleder C. Biological Psychiatry, 2016, 79, (7) 604-612. doi: 10.1016/j.biopsych.2015.11.018. Abstract Over recent years, the interest in the endocannabinoid system (ECS) as a new target for the treatment of schizophrenia has evolved. The ECS represents one of the most relevant neurotransmitter systems in the brain and mainly fulfills a homeostatic role in terms of neurotransmission but also with respect to inflammatory processes. Two main approaches to the modulation of endocannabinoid functioning have been chosen so far. First, the selective blockade or inverse agonism of the type 1 cannabinoid receptor has been tested for [...]
Lire la suiteChapter 97 - Cannabidiol for the Treatment of Drug Use Disorders R.G. dos SANTOS, J.E.C. HALLAK, W. ZUARDI, J.A. de SOUZA in "Handbook of Cannabis and Related Pathologies". "Biology, Pharmacology, Diagnosis, and Treatment", 2017, Pages 939-946 https://doi.org/10.1016/B978-0-12-800756-3.00113-7 Abstract The problematic use of psychoactive substances like alcohol, cannabis, cocaine, amphetamines, heroin, and nicotine carry a series of health, economic, and social costs to individuals and society. Although pharmacological treatments for alcohol, heroin, and nicotine abuse or dependence are available, there is no approved medication for the treatment of cannabis and stimulant dependence. Cannabidiol (CBD), a nonpsychotomimetic cannabinoid present in the cannabis plant, has anxiolytic, antipsychotic, antiepileptic, [...]
Lire la suiteCannabidiol and Canabis Use Disorder María S. García-Gutiérrez, Francisco Navarrete, Adrián Viudez-Martínez, Ani Gasparyan, Esther Caparrós, Jorge Manzanares Chapter, In book : "Cannabis Use Disorders", 2018, pp 31-42 DOI: 10.1007/978-3-319-90365-1_5 Abstract Cannabis use disorders (CUD) represent a serious public health problem in occidental societies. Despite their devastating social, health, and economic impact, to date no pharmacological treatment has been approved for the clinical management of cannabis dependence. Cannabidiol (CBD), one of the main compounds—together with Δ9-THC—present in the plant Cannabis sativa, has been reported to possess anxiolytic, antidepressant, and antipsychotic-like effects and neuroprotective properties. And, contrary to Δ9-THC, CBD does not appear to have addictive properties. Taken [...]
Lire la suiteA Cross-Sectional Study of Cannabidiol Users Jamie Corroon and Joy A. Phillips Cannabis and Cannabinoid Research, 2018, 3, 1, 152-161. https://doi.org/10.1089/can.2018.0006 Abstract Introduction: Preclinical and clinical studies suggest that cannabidiol (CBD) found in Cannabis spp. has broad therapeutic value. CBD products can currently be purchased online, over the counter and at Cannabis-specific dispensaries throughout most of the country, despite the fact that CBD is generally deemed a Schedule I controlled substance by the U.S. Drug Enforcement Administration and renounced as a dietary supplement ingredient by the U.S. Food and Drug Administration. Consumer demand for CBD is high and growing, but few studies have examined the [...]
Lire la suiteCannabidiol : a hope to treat non‑motor symptoms of Parkinson’s disease patients Sidra Saleem & Arsalan Anwar European Archives of Psychiatry and Clinical Neuroscience, 2019 https://doi.org/10.1007/s00406-019-01023-y We read an article, “Is Cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms” by Cripp [1], the novel discussion and explanation of the role of cannabidiol (CBD) in Parkinson’s disease (PD) inspired us to write our feedback. We would like to share our views on the role of CBD in the prevention and treatment of movement disorders. CBD is one of the main components of Cannabis sativa investigated previously for its neuroprotective effects. Its mechanism of action [...]
Lire la suiteCannabis sativa L. and Nonpsychoactive Cannabinoids : Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer Federica Pellati, Vittoria Borgonetti, Virginia Brighenti, Marco Biagi, Stefania Benvenuti, and Lorenzo Corsi Hindawi, BioMed Research International, 2018, Volume 2018, Article ID 1691428, 15 pages https://doi.org/10.1155/2018/1691428 Abstract In the last decades, a lot of attention has been paid to the compounds present in medicinal Cannabis sativa L., such as Δ9- tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD), and their effects on inflammation and cancer-related pain.The National Cancer Institute (NCI) currently recognizes medicinal C. sativa as an effective treatment for providing relief in a number of symptoms associatedwith cancer, including pain, [...]
Lire la suiteCannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models Pabitra Hriday Patra, Melissa Barker-Haliski, H. Steve White, Benjamin J. Whalley, Sarah Glyn, Haramrit Sandhu, Nicholas Jones, Michael Bazelot, Claire M. Williams, Alister James McNeish Epilepsia, 2018, 1–12. DOI: 10.1111/epi.14629 Summary Objective : Epilepsy is a progressive neurological disease characterized by recurrent seizures and behavioral comorbidities. We investigated the antiseizure effect of cannabidiol (CBD) in a battery of acute seizure models. Additionally, we defined the disease‐modifying potential of chronic oral administration of CBD on associated comorbidities in the reduced intensity status epilepticus–spontaneous recurrent seizures (RISE‐SRS) model of temporal lobe [...]
Lire la suiteCannabinol and Neuropathic Pain P.W. Brownjohn and J.C. Ashton Neuropathic Pain, 2012, chap. 4, 79-102 1. Introduction Cannabinoids are drugs that are either derived from cannabis or that induce similar behavioural and physiological effects to cannabis. They fall into three classes: those that are produced by plants of the Cannabis genus, termed phytocannabinoids (plant cannabinoids); those that are produced within the body, termed endocannabinoids (endogenous cannabinoids); and those that are produced synthetically to mimic the pharmacology of naturally occurring cannabinoids. Cannabinoids stand in relation to cannabis as opioids such as codeine, pethidine, fentanyl, and methadone stand in relation to opium. While opium and opioids [...]
Lire la suiteCannabidiol : Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez-Ruiz, Jacqueline French, Charlotte Hill, Russell Katz, Vincenzo Di Marzo, Didier Jutras-Aswad, William George Notcutt, Jose Martinez-Orgado, Philip J. Robson, Brian G. Rohrback, Elizabeth Thiele, Benjamin Whalley, and Daniel Friedman Epilepsia, 2014, 55, 6, 791–802, doi: 10.1111/epi.12631 SUMMARY To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders.Wesummarize the presentations from a conference in which invited participants reviewed relevant aspects of the physiology, mechanisms of action, pharmacology, and data [...]
Lire la suite